RxDoctor Payments Data

Vijay Kanakadandi, MD

Gastroenterology · Saint Joseph, MONPI 1063728665

Payments from drug & device makers

$2,432in general payments, 2019–2025

Across 54 payments — averaging $45.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$215
  • Sanofi$121
  • Janssen Scientific Affairs, LLC$117
  • Ardelyx, Inc.$79
  • Phathom Pharmaceuticals, Inc.$73
  • plus $407 from 13 others

What the payments were for

  • Travel & lodging$1,03443%
  • Food & beverage$1,39757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,432 in reported general payments places this provider in the 55th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$136,516
Medicare patients
516
Services billed
1,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$279,082
XifaxanRifaximin27$84,292
LinzessLinaclotide30$24,488
CreonLipase/Protease/Amylase15$20,430
MotegrityPrucalopride Succinate16$9,001
TrulancePlecanatide12$7,684
Omeprazole163$2,141
Ursodiol11$1,587
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl76$1,348
Esomeprazole Magnesium35$1,047
Spironolactone25$554
Pantoprazole Sodium41$460
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl26$434
Famotidine39$369
Dicyclomine Hcl15$249

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$34$279,08211 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$21$91,97639 claims
AbbVieLinzess, Creon$215$44,91745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →